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Comparative assessment of methicillin
resistant Staphylococcus aureus diagnostic
assays for use in resource-limited settings
A. Ayebare1,2* , L. M. Bebell3,4, J. Bazira1, S. Ttendo1, V. Katawera5, D. R. Bangsberg6, M. J. Siedner1,3,4, P. G. Firth7 and
Y. Boum II1,2*
Abstract
Background: The rise of methicillin-resistant Staphylococcus aureus (MRSA) is a global health concern. Paucity
of data on MRSA carriage prevalence and diagnostic methods in resource-limited settings hampers efforts to
define the problem and plan an appropriate response. Additionally, high variability in cost and logistical
characteristics of MRSA screening methods may impede infection control efforts. We compared the
performance of locally-available chromogenic agar BD CHROMagar MRSA II and two PCR-based assays (Hain
GenoQuick MRSA and Cepheid Xpert SA Complete) for the detection of asymptomatic MRSA carriage in nasal
swabs.
Results: During 2015, we enrolled 500 patients from five hospital wards at a Ugandan regional referral
hospital. We found 30% prevalence of methicillin-sensitive Staphylococcus aureus (MSSA) nasal carriage, and
5.4% MRSA nasal carriage prevalence. Compared to a composite reference standard defined as a positive test
result on any one of the three assays, Hain GenoQuick MRSA demonstrated the highest sensitivity (96%)
followed by direct plating on CHROMagar at (70%), with the lowest sensitivity observed with Xpert SA
Complete (52%). Cepheid Xpert provided the most rapid results (< 1 h) but was the most expensive (US $45–
50/test). Substantially more labor was required for the Hain GenoQuick MRSA compared to Xpert SA
Complete or CHROMagar tests.
Conclusion: MRSA nasal carriage prevalence rates were low, and high diagnostic sensitivity was achieved
using Hain GenoQuick MRSA. Chromogenic media had significantly lower sensitivity, but may represent a
viable local option given its lower cost compared to PCR-based assays.
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Background
Staphylococcus aureus is one of the most common bac-
terial pathogens associated with both nosocomial and
community-acquired infections [1]. Due to its com-
mensal nature on human skin and mucous membranes,
S. aureus spreads readily from person-to-person, causing
infections in skin, soft tissues and the bloodstream [2].
The increasing use of antibiotics contributes to
emergence of methicillin-resistant strains of S. aureus
(MRSA) [3]. MRSA infections remain a significant cause
of hospital-acquired infections [4, 5]; accounting for up
to 75% of all S. aureus isolates from patients with skin
and soft-tissue infections among patients seen in
emergency departments in the United States [3].
Patients with invasive MRSA infections are often colo-
nized with MRSA or acquire it from healthcare workers
[6]. In many high-resource settings, patients are tested
for MRSA carriage on hospital admission and may
undergo isolation or decontamination to reduce MRSA
transmission [7, 8]. Towards this end, several detection
methods have been used to evaluate MRSA carriage, in-
cluding polymerase chain reaction (PCR)-based assays
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and culture using chromogenic agar. Although there is
no universal reference standard for MRSA testing, mo-
lecular methods such as PCR are often used in high-re-
source settings to detect nasal MRSA carriage, reducing
reporting times from days to hours, compared to
traditional culture techniques [9].
In resource-limited settings, however, few facilities use
molecular methods due to high test costs, and lack of ne-
cessary equipment and appropriately-trained personnel.
There is a paucity of data about the relative performance
of laboratory tests to diagnose MRSA nasal carriage in
resource-limited settings. Therefore, we assessed three
screening methods for MRSA nasal carriage with varying
characteristics of test speed, cost, human resource, labora-
tory requirements, and diagnostic sensitivity.
Methods
Participants, specimen and data collection, and quality
control
We performed a cross-sectional study of 500 adult
patients presenting for care to Mbarara Regional Referral
Hospital (MRRH), a 608-bed hospital located in
Mbarara, approximately 265 km southwest of Uganda’s
capital Kampala. The patient population resides in a pre-
dominantly rural, agricultural area. Between January to
October 2015, one hundred patients were enrolled
consecutively from each of five hospital departments:
inpatient surgery ward, in-patient medicine ward, in-pa-
tient maternity ward, general out-patient department,
and the out-patient Immune Suppression Syndrome
(ISS) Clinic, which exclusively serves patients living with
HIV until the enrollment target was reached and then
enrollment was begun in the next department. Adult
participants ≥18 years of age cared for at any of the five
hospital departments were eligible for enrollment. Exclu-
sion criteria were age < 18 years, inability to speak Eng-
lish or the local language Runyankole, and inability for
the participant or their next-of-kin to provide informed
consent. Participants included were part of a clinical
study assessing prevalence and correlates of MRSA and
MSSA nasal carriage at a Ugandan regional referral hos-
pital [10]. Study participants had their bilateral anterior
nares swabbed with two sterile Dacron-tipped dual-
swabs representing a combined sample of both nares.
Each Dacron-tipped collection device has two swabs giv-
ing a total of four swabs. Three were used for the MRSA
detection methods, and the remaining swab was kept re-
frigerated for retesting. Swabs were transported same-
day to the Epicentre laboratory on-site for refrigeration
and processing within 24 h. Quality control procedures
were performed using commercially available bacteria
strains ATCC 33591 MRSA and ATCC 25923 MSSA on
each new lot of testing kits. All samples producing
invalid and erroneous results were repeated once.
Demographic characteristics were captured using inves-
tigator-designed questionnaires.
BD CHROMagar MRSA II
One swab (Copan Tran-system Liquid Amies double
swab) was inoculated directly onto nutrient-enriched se-
lective agar media (CHROMagar MRSA II, BD Diagnos-
tic Systems, Sparks, USA) and incubated under aerobic
conditions at 37 °C for 24 h according to the manufac-
turer’s instructions. After 24 h, each plate was examined
for colony growth and color. All mauve colonies under-
went further identification including Gram stain and
coagulase testing to be confirmed as MRSA. Culture-
negative plates were further incubated and examined at
48 h and discarded if negative.
Xpert SA nasal complete
The second swab was processed for the Cepheid Xpert
SA Nasal Complete assay (Cepheid, Sunnyvale, USA) ac-
cording to the manufacturer’s instructions and run on
the Cepheid Xpert SA Complete platform. Fluorescent
signals of target DNA, SA-spa/MRSA-mecA and mecA
and SCCmec) were measured and results were provided
automatically by the GeneXpert machine. Results were
reported positive for S. aureus if the spa gene was de-
tected above threshold limits, and samples were reported
MRSA-positive if spa, mecA and SCCmec genes were all
detected above threshold limits. The minimum cycle
threshold (Ct) detection limit for all genes was a Ct of
10, and the maximum Ct detection limit for spa, mecA
and SCCmec was 35, 36, and 38, respectively.
Hain GenoQuick MRSA
The third swab was run on the Hain GenoQuick MRSA
assay (Hain Life Science, Nehren, Germany) according
to the manufacturer’s instructions. A Lack of MRSA-
positive samples in the first 100 swabs and documented
30-fold differences in level of detection led study investi-
gators to optimize the Hain GenoQuick MRSA amplifi-
cation procedure [11]. The remaining 400 samples were
tested under a revised protocol where double the
amount of DNA lysate was used, improving the test’s
level of detection. As a result of logistical shortage of
Hain GenoQuick kits, only 70 of the initial 100 samples
were retested using the revised protocol, and 470 total
sample results are reported. Results were then inter-
preted as positive or negative for MRSA for the assay
according to the manufacturer’s instructions.
Data entry and analysis
Demographic data and microbiology results were manu-
ally entered into a REDCap database hosted at Partners
Healthcare in Boston, USA [12]. Analyses were per-
formed in Stata version 12 (StataCorp, College Station,
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USA). As our primary interest was in assessing test sensi-
tivity as the most relevant measure for infection control
purposes, we created a composite reference standard
(CRS), defining a sample as positive by the CRS if it tested
positive by one or more individual tests: 1) BD CHROMa-
gar, 2) Cepheid Xpert SA Nasal Complete, 3) Hain
GenoQuick. We then calculated sensitivity of each test
compared to the CRS. We carried out activity/task ana-
lysis by observation of these three test methods to define
outcomes, including cost, time, and logistical needs.
Results
We enrolled 500 participants, 100 from each of five hos-
pital wards (Fig. 1). MRSA nasal carriage prevalence was
5.4% using the CRS (n = 27, 95% confidence interval [CI
3.6–7.8%]. Of 500 samples tested for MRSA using the
Cepheid Xpert SA Complete assay, one yielded an in-
valid result, leaving 499 samples for analysis. Of these
499 samples, 14 were positive for MRSA (2.8%). Of 500
samples directly cultured onto CHROMagar MRSA II,
44 (8.8%) had characteristic mauve colony growth. Of
these, 40 (90.9%) grew after 24 h and19 (43.2%) were
confirmed MRSA with a positive tube coagulase test and
Gram stain demonstrating gram-positive cocci. One of
four plates with growth at 48 h (but not at 24 h) was also
confirmed as MRSA. Of 470 samples tested for MRSA
using the Hain GenoQuick MRSA revised protocol
assay, 24 (5.1%) were MRSA positive.
The sensitivity of each assay for MRSA detection com-
pared to the CRS was 96% (95% CI 81–100%) for Hain
GenoQuick MRSA, 70% (95% CI 50–86%) for CHRO-
Magar, and 52% (95% CI 32–71%) for GeneXpert SA
nasal complete (Table 1). The cost per test was US
$6.50–7.50 for CHROMagar MRSA with an 18–48 h
turnaround time, $45–50 for GeneXpert SA Nasal
Complete with a 1.25-h turnaround time, and $10–15
for Hain GenoQuick MRSA with a 3.5-h turnaround
time (Table 2).
Discussion
The prevalence rate for MRSA nasal carriage was sur-
prisingly low in our setting, and method comparison
Fig. 1 Flow diagram of samples collected and results from all three testing methods
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showed that the Hain GenoQuick MRSA assay demon-
strated a high diagnostic sensitivity compared to the
CRS. Chromogenic media had significantly lower sensi-
tivity than the Hain GenoQuick MRSA.
Significant discrepant results between PCR assays may
have resulted from, possibly due to MRSA genetic variants
yielding undetectable or unstable amplification products
[13–15]. Some studies have reported up to 30-fold higher
level of detection for the Hain Geno Quick assay com-
pared to the Cepheid Xpert SA Complete [11, 16, 17], and
the relatively low sensitivity of the Cepheid Xpert SA
Complete assay may have resulted from cycle time cut-off
limits for the amplification target [15, 18, 19]. For the
Hain GenoQuick MRSA assay, optimization was required
to enhance detection, and required technical expertise and
troubleshooting. Although precautions were taken to
minimize PCR assay interference, it is also possible that
invalid Cepheid GeneXpert results were due to the pres-
ence of PCR inhibitors in swab specimens, including
mucin, blood, dust, or air bubbles. Compared to the CRS,
culture-based methods demonstrated low sensitivity,
which could be due to low bacterial density in nasal swab
specimens. Similarly, participants’ current or recent anti-
biotic use may have rendered MRSA organisms non-viable
on culture, or lowered the bacterial concentration below
the PCR assays’ limits of detection. Compared to PCR-
based assays, culture-based methods are disproportion-
ately affected by bacterial concentrations, decreasing
sensitivity [16, 17, 18].
The three methods differed greatly in cost, processing,
turnaround time, and technical requirements with PCR
platforms significantly more expensive especially due to
Table 1 Performance of each diagnostic test, compared to the composite reference standard (CRS), defined as a positive result on
one or more of the individual tests: Hain GenoQuick, BD CHROMagar, Cepheid Xpert SA Nasal Complete
aCRSMRSA (+)
(n = 27)
CRS MRSA (−)
(n = 472)
Sensitivity
(%, 95 CI)
GenoQuick (n = 470)
MRSA (+) 26 0 96 (81–100)
MRSA (−) 1 443
CHROMagar (n = 500)
MRSA (+) 19 0 70 (50–86)
MRSA (−) 8 472
GeneXpert SA complete (n = 499)
MRSA (+) 14 0 52 (32–71)
MRSA (−) 13 473
CI Confidence interval
aA true positive culture was defined as MRSA detected by one or more of the three tests, and also called the composite reference standard (CRS)
Table 2 Comparison of detection methods by factors influencing decision to adopt a specific test
Variable Assay
CHROMagar MRSA Cepheid Xpert SA Complete Hain GenoQuick
Initial investment cost
(equipment, accessories)
US $14,400 US $43,000 US $23,900
Cost per test US $6.50–7.50 US $45–50 US $10–15
Hands-on time
per sample
4–5 min < 1min ~ 15 min
Number of Samples
per Run
1 sample per plate 4 samples per run 12 samples per run
Testing time 18–48 h < 1 h (50 mins) 2.5 h
Total turn-around-time 18–48 h 1.25 h 3.5 h
Human resource
considerations
Technically demanding Not technically demanding Technically demanding
Challenges Definite identification as MRSA requires
confirming isolates as S. aureus with a
coagulase test, which is not included in
the test kit nor specified by the
manufacturer
High failure rate –sample debris can
clog pre-filter with particulates, leading
to cartridge failure. No sample
preparation is recommended by the
manufacturer
Extraction, amplification and detection
processes are cumbersome and hands-
on. Assay needed to be optimized by
doubling the amount of DNA extract,
which was not specified by the
manufacturer
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up-front costs, some more required specialized equipment
and considerable technical expertise but faster turnaround
times may lead to downstream cost savings in infection pre-
vention and control measures. The Hain GenoQuick MRSA
assay is time-consuming, and requires technical expertise
and specialized accessories/equipment, limiting its role in
field-based MRSA screening whereas the Cepheid Xpert SA
Complete assay is an easy-to-use and rapid point-of-care test
requiring little hands-on time. Despite having the longest
turnaround time and relatively low sensitivity culture-based
method is easier to implement in resource-limited settings,
balancing cost, technical expertise, and human resource
requirements. Chromogenic methods are considered an im-
provement over conventional culture methods and surveil-
lance testing of multiple body sites can significantly improve
detection rates [20, 21].
Our study is one of the first to compare three method-
variable assays for performance in a resource-limited
setting. Strengths of our study include the large sample
size, diverse patient population and use of multiple con-
current testing regimens. Weaknesses of the study in-
clude the need to optimize the Hain GenoQuick MRSA
assay, and lack of molecular typing of MRSA grown in
culture due to resource limitations.
Conclusion
We recommend that individual sites considering active
MRSA surveillance make decisions about testing
methods based upon local conditions, including known
risk groups, carriage and infection rates, organizational
structures, and hygiene policies. The Hain GenoQuick
MRSA is the most advantageous method for MRSA
detection in centralized surveillance programs, while
GeneXpert SA Nasal complete assay is better suited to
high-risk settings in need of rapid results. Where
resources are limited, CHROMagar MRSA II culture-
based method is a rational option, and whose sensitivity
can be improved by swabbing of multiple anatomic sites.
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